The other reproductive life stages have their pages: GLP-1s and PCOS: What the Studies Show, GLP-1s and Pregnancy Planning: What the Labels Say, GLP-1s and Breastfeeding: What the Labels Say. Menopause is different, and the difference is the point. The evidence here is an absence with one small study standing next to it, and the useful thing a reader can take away is precision about exactly what that study can and cannot carry.
The labels say nothing at all
The words menopause and postmenopausal appear nowhere in the current US labels for Wegovy, Ozempic, the shared Rybelsus and Ozempic tablets label, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity, Byetta or Foundayo, checked on November 4, 2026. No indication, no warning, no specific population statement, no dosing note. The trials behind these labels report sex in their baseline tables, but they do not report menopausal status, so the labels have nothing to say on the subject in either direction.
An absence in a label is not a verdict. It does not mean these medicines are unsafe at this stage of life, and it does not mean they are beneficial for anything associated with it. It means the question was not studied in a way that reached the labelling, which leaves the individual questions exactly where they belong, with a clinician who knows the person asking them.
The one study, and its numbers
One piece of research circulates whenever this subject comes up: a 2024 study in the journal Menopause, looking at postmenopausal women treated with semaglutide for overweight or obesity for at least three months. It was a retrospective cohort, meaning the researchers went back through records of care that had already happened, rather than assigning treatments. It compared 16 women using hormone therapy with 90 who were not.
Total body weight loss was higher in the hormone therapy group at every checkpoint: 7 percent against 5 at three months, 13 against 9 at six, 15 against 10 at nine, and 16 against 12 at twelve. The association held after adjustment for confounders. The authors concluded that larger studies should be conducted to confirm the result, which is the right size of claim for what they had.
What 16 people can and cannot support
A retrospective cohort compares groups that chose their own treatments, which means the two groups can differ in ways nobody measured. The 16 women on hormone therapy were not randomly assigned to it; they differ from the 90 by everything that led them and their doctors there, and a statistical adjustment can only account for factors somebody recorded. Sixteen people in one arm is also simply few, and every percentage in the table rests on them.
So the study is a reason to ask a question, not an answer to one. Nothing in it tells any individual what hormone therapy would do for her weight on a GLP-1, and nothing in it is guidance about hormones. It is early evidence that menopausal status and hormone therapy deserve study in this class, which is precisely how the authors framed it. Holding a small study to its actual size is the core skill taught at How to Read a GLP-1 Study Headline: Relative Risk, Subgroups and Funding, and this is one of the cleaner practice cases around.
Two explanations arriving in the same year
There is a practical problem that needs no new trial to describe. Several complaints people associate with the menopausal transition also appear in these labels as adverse reactions of the class, fatigue among them, and weight change is in the conversation on both sides. When two things that each plausibly explain a symptom arrive in the same year of someone's life, attribution by memory is close to impossible. A person trying to reconstruct from memory which month the tiredness started, and whether it was before or after a dose change, is doing a retrospective cohort of one, with the same limits as any retrospective cohort.
A dated record is what makes the question answerable: doses with their dates, weight with its dates, and a short note about how the weeks actually went. Then the conversation with a clinician is about evidence rather than recollection. Which cause is likelier in any given case is a judgement that needs the person and their history in the room. The neighbouring pages are Tired on a GLP-1? Tracking Energy Alongside Your Doses and When the Data and How You Feel Disagree.
Contraception is the one specific point
Amid the silence, one instruction exists and it is specific. Pregnancy remains possible during the menopausal transition, so contraception stays a live question rather than a settled one through perimenopause. The tirzepatide labels carry their own instruction about oral contraceptives, which is covered in full at Tirzepatide and the Pill: What the Label Says About Birth Control. Which approach fits a particular person, at a particular stage, on a particular medicine, is a prescriber conversation, and the transition years are exactly when that conversation deserves precision rather than assumption.
Frequently asked questions
Do GLP-1 medications help with menopause symptoms?
No evidence in hand supports that in either direction. The words menopause and postmenopausal appear nowhere in the current US labels for any medicine in this class, checked on November 4, 2026, and the trials behind those labels report sex in their baseline tables but not menopausal status. Whether a GLP-1 affects any menopausal symptom is therefore an open question with no label and no trial behind it, and individual symptoms belong with a clinician.
What did the hormone therapy and semaglutide study find?
A 2024 retrospective cohort study in the journal Menopause followed postmenopausal women treated with semaglutide for overweight or obesity for at least three months, comparing 16 women using hormone therapy with 90 who were not. Total body weight loss was higher in the hormone therapy group at 3, 6, 9 and 12 months: 7 against 5 percent, 13 against 9, 15 against 10, and 16 against 12, an association that held after adjustment for confounders. The authors called for larger studies to confirm the result.
Should I start or change hormone therapy to improve my GLP-1 results?
That is a prescriber subject entirely, and one small retrospective study cannot inform it. Sixteen people in one arm of a retrospective cohort cannot tell any individual what hormone therapy would do for their weight, and nothing in the study constitutes advice about hormones. Decisions about hormone therapy belong with a clinician who knows the full history, and the same goes for any question raised by reading about the study.
Why does fatigue on a GLP-1 feel impossible to attribute during the menopausal transition?
Because the same complaint plausibly belongs to both. Fatigue is listed in these labels as an adverse reaction of the class, and it is also something people associate with the menopausal transition, with weight change in the conversation on both sides. When two candidate explanations arrive in the same year of someone's life, memory cannot sort them. A dated record of doses and how each week went is what makes the question answerable with a clinician.
Do I still need contraception during perimenopause if I am on a GLP-1?
Pregnancy remains possible during the transition, which is why contraception is a live question rather than a settled one. The tirzepatide labels carry their own instruction about oral contraceptives, and that instruction is covered in detail in the tirzepatide and the pill guide. The right contraceptive approach alongside a GLP-1 is a conversation with a prescriber.